A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies (NCT04227847)
A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
🩺 Plain-English Summary (8th-Grade Level)
This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for participants with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and MDS. A side effect is anything the drug does besides treating cancer. This study will have seven groups or "parts." * Part A will find out how much SEA-CD70 should be given to participants * Part B will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat participants with MDS. * Part C will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat participants with AML. * Part D will find out how much SEA-CD70 with azacitidine should be given to participants * Part E will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat participants with MDS or MDS/AML that has not been treated. * Part F will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat participants with MDS or MDS/AML. * Part G will find out how much SEA-CD70 with azacitidine and with venetoclax should be given to participants with AML. Also, to evaluate safety and tolerability of PF-08046040 in combination with azacitidine and venetoclax in participants with previously untreated AML who are unfit for standard induction chemotherapy.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (53 Sites)
Showing the first 25 of 53 sites.
- University of Alabama at Birmingham — Birmingham, Alabama
- University of Alabama at Birmingham — Birmingham, Alabama
- Dept. of Medicine, UAB ONeal Comprehensive Cancer Center — Birmingham, Alabama
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- IP Address: City of Hope Investigational Drug Services(IDS) — Duarte, California
- Ronald Reagan UCLA Medical Center — Los Angeles, California
- UCLA Hematology-Oncology Clinic — Los Angeles, California
- Colorado Blood Cancer Institute, Lab — Denver, Colorado
- Colorado Blood Cancer Institute — Denver, Colorado
- Presbyterian/St. Luke's Medical Center — Denver, Colorado
- The University of Kansas Cancer Center ,Investigational Drug Services — Fairway, Kansas
- The University of Kansas Clinical Research Center — Fairway, Kansas
- The University of Kansas Hospital — Kansas City, Kansas
- University of Kansas Hospital Cambridge North Tower A — Kansas City, Kansas
- University of Kansas Medical center Medical office building — Kansas City, Kansas
- University of Kansas Medical Center Research Institute — Kansas City, Kansas
- The University of Kansas Cancer Center - Overland Park — Overland Park, Kansas
- The University of Kansas Cancer Center - Indian Creek Campus — Overland Park, Kansas
- The University of Kansas Cancer Center — Westwood, Kansas
- Norton Hospitals, Inc — Louisville, Kentucky
- Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD — Louisville, Kentucky
- Norton Cancer Institute, St. Matthews Campus — Louisville, Kentucky
- Norton Women & Children's Hospital — Louisville, Kentucky
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myelodysplastic Syndrome
- Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders — Basking Ridge, New Jersey
- Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes? — Hamilton, Ontario
- A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) — Tampa, Florida
- Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) — Berkeley, California
- A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions — Gilbert, Arizona
Explore by condition: All Myelodysplastic Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.